Brand Name(s) in US
ChemicalBook > CAS DataBase List > Ertapenem

Ertapenem

Brand Name(s) in US
Product Name
Ertapenem
CAS No.
153832-46-3
Chemical Name
Ertapenem
Synonyms
MK-0826;EOS-61119;ERTAPENEM;Ertapenem D4;Ertapenem Powder;Ertapenem Monomer;Ertapenem USP/EP/BP;ERTAPENEM(FORR&DONLY);Ertapenem hydrochloride;ErtapenemDiscontinued See E635000
CBNumber
CB0722982
Molecular Formula
C22H25N3O7S
Formula Weight
475.51
MOL File
153832-46-3.mol
More
Less

Ertapenem Property

Boiling point:
813.9±65.0 °C(Predicted)
Density 
1.55±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
soluble in DMSO, Methanol
pka
4.03±0.10(Predicted)
form 
Foam
color 
Brown
CAS DataBase Reference
153832-46-3
More
Less

Safety

Hazardous Substances Data
153832-46-3(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

AK Scientific
Product number
E132
Product name
Ertapenem
Packaging
5mg
Price
$150
Updated
2021/12/16
Biorbyt Ltd
Product number
orb134782
Product name
Ertapenem
Purity
>99%
Packaging
250mg
Price
$615.4
Updated
2021/12/16
Matrix Scientific
Product number
098876
Product name
Ertapenem hydrochloride
Purity
95+%
Packaging
250mg
Price
$793
Updated
2021/12/16
Biorbyt Ltd
Product number
orb134782
Product name
Ertapenem
Purity
>99%
Packaging
1g
Price
$1208.7
Updated
2021/12/16
Biorbyt Ltd
Product number
orb134782
Product name
Ertapenem
Purity
>99%
Packaging
100mg
Price
$414.8
Updated
2021/12/16
More
Less

Ertapenem Chemical Properties,Usage,Production

Brand Name(s) in US

Invanz

Description

Ertapenem is another synthetic carbapenem with a rather complex side chain at C-3. It is used once daily parenterally, with special application against anaerobes. As with meropenem, the 4-β-methyl group confers stability toward dehydropeptidase-1 It is not active against pseudomonads or acinetobacteria and, therefore, should not be substituted for imipenem or meropenem. It is relatively strongly bound to serum proteins, so it has a prolonged half-life, making it more convenient to use than the other carbapenems when its spectrum warrants this. Its reported indications include complicated intra-abdominal and complicated skin/skin structure infections caused by sensitive organisms (for intra-abdominal: Escheri chia coli, Clostri di um clostri doforme, Bacteroi des fragilis, and Peptostreptococcus sp; for skin/skin structures: Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pyogenes, E.coli, or Peptostreptococcus sp.). It can be administered once daily.

Uses

Ertapenem is a long-acting parenteral cabapenem. Ertapenem has bactericidal activity against a variety of gram-negative pathogens, some gram positive strains, and Haemopilus influenzae. Ertapenem has shown to inactivate L,D-transpeptidase, an enzyme responsible for in vitro cross-linking of Mycobacterium tuberculosis peptidoglycan.

Uses

Antibacterial. Invanz (Merck).

Definition

ChEBI: Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections includ ng intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.

Antimicrobial activity

Activity against aerobic and anaerobic pathogens is comparable to that of imipenem: MIC values for Gramnegative bacilli (with the exception of Ps. aeruginosa) are generally lower and those for Gram-positive cocci higher.
Ertapenem is stable to most serine β-lactamases, but is hydrolyzed by serine carbapenemases and metallo- β-lactamases.

General Description

Ertapenem (Invanz, for injection) is a synthetic 1-β-methylcarbapenem that is structurally related to β-lactam antibiotics,particularly the thienamycin group. Its mechanism ofaction is the same as that of other β-lactam antibiotics. Thestructure resists β-lactamases and dehydropeptidases.
Ertapenem is indicated for the treatment of moderate tosevere infections caused by susceptible strains causing complicatedintra-abdominal infections such as Escherichia,Clostridium, Peptostreptococcus, and Bacteroides. Theantibiotic is also indicated for complicated skin and skinstructure infections including diabetic foot infections (withoutosteomyelitis). Treatable strains include Staphylococcus(MSSA), Streptococcus, Escherichia, Klebsiella, Proteus,and Bacteroides. Ertapenem is also indicated for community-acquired pneumonia caused by S. pneumoniae,Haemophilus infljuenzae, and M. catarrhalis. Complicatedurinary tract infections and acute pelvic infections round outthe indications for ertapenem.

Pharmacokinetics

Cmax 1 g intramuscular: c. 67 mg/L after 2 h
1 g intravenous infusion (30 min): c. 155 mg/L end infusion
Plasma half-life: c. 4 h
Volume of distribution: c. 0.12 L/kg (steady state)
Plasma protein binding: 85–95%
Absorption after intramuscular injection is essentially complete with 90% bioavailability. The modestly extended plasma half-life allows once-daily dosing.
Excretion is predominantly by the renal route, about 80% being recovered in the urine within 24 h. About 40% is eliminated unchanged, the rest as a biologically inactive ringopened metabolite. Dosage should be reduced in severe renal impairment.

Clinical Use

Complicated intra-abdominal infections
Complicated skin and skin structure infections, including diabetic foot
infections without osteomyelitis
Community acquired pneumonia
Complicated urinary tract infections including pyelonephritis
Acute pelvic infections including postpartum endomyometritis, septic
abortion and postsurgical gynecologic infections
Prophylaxis of surgical site infection following elective colorectal surgery

Side effects

Ertapenem appears to be generally well tolerated. The most common drug-related adverse experiences are diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis (2.1%), phlebitis/thrombophlebitis (1.3%) and vomiting (1.1%). Seizures have occasionally been reported (0.5%) in patients with a history of disorders of the CNS.

Drug interactions

Potentially hazardous interactions with other drugs Antiepileptics: concentration of valproate reduced - avoid concomitant use

Metabolism

After intravenous infusion of radiolabelled 1 g ertapenem, the plasma radioactivity consists predominantly (94%) of ertapenem. The major metabolite of ertapenem is the ring-opened derivative formed by dehydropeptidaseI-mediated hydrolysis of the beta-lactam ring.
Approximately 80% of a dose is recovered in urine and 10% in faeces. Of the 80% recovered in urine, approximately 38% is excreted as unchanged ertapenem and approximately 37% as the ring-opened metabolite.

Ertapenem Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Ertapenem Suppliers

Suizhou HongQi Chemical Corporation Limited
Tel
0722-3257376 13026100080
Fax
0722-3257381
Email
774811011@qq.com
Country
China
ProdList
64
Advantage
55
Absin Bioscience Inc.
Tel
021-38015121 15000105423
Email
wulan@absin.cn
Country
China
ProdList
24731
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
shilang(zhuoli group)-pharma(nanjing) co.,ltd.
Tel
86-25-87797880,81,82 -809
Fax
86-25-85318152
Email
shilang@shilang-pharma.com
Country
China
ProdList
40
Advantage
55
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
chenyj@titansci.com
Country
China
ProdList
14103
Advantage
59
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Shanghai Longsheng chemical Co.,Ltd.
Tel
021-58099652-8005 13585536065
Fax
021-58099609
Email
bin.wu@shlschem.com
Country
China
ProdList
9809
Advantage
59
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8836
Advantage
52
China Langchem Inc.
Tel
0086-21-58956006
Fax
0086-21-58956100
Country
China
ProdList
7811
Advantage
57
More
Less

View Lastest Price from Ertapenem manufacturers

Hebei Weibang Biotechnology Co., Ltd
Product
Ertapenem 153832-46-3
Price
US $9.90/KG
Min. Order
1KG
Purity
99%
Supply Ability
10 mt
Release date
2024-11-21
Shaanxi Dideu Medichem Co. Ltd
Product
Ertapenem 153832-46-3
Price
US $1.00-1.00/KG
Min. Order
1g
Purity
99%
Supply Ability
50tons
Release date
2020-05-07
ShenZhen H&D Pharmaceutical Technology Co., LTD
Product
Ertapenem 153832-46-3
Price
US $0.00-0.00/mg
Min. Order
10mg
Purity
0.98
Supply Ability
10g
Release date
2024-04-26

153832-46-3, ErtapenemRelated Search:


  • ERTAPENEM
  • (4r,5r,6s)-3-[(3s,5s)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  • ERTAPENEM(FORR&DONLY)
  • (4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbaMoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  • Ertapenem hydrochloride
  • 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid,3-[[(3S,5S)-5-[[(3-carboxyphenyl)aMino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-,(4R,5S,6S)-
  • sodium(4R,5S,6S)-3-(((3S,5S)-5-((3-carboxylatophenyl)carbamoyl)pyrrolidin-1-ium-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
  • EOS-61119
  • ErtapenemDiscontinued See E635000
  • MK-0826
  • Ertapenem USP/EP/BP
  • Ertapenem D4
  • Ertapenem Powder
  • Benzaldehyde,5-chloro-3-(1,1-dimethylethyl)-7-hydroxy-
  • Ertapenem Monomer
  • 153832-46-3
  • 3832-46-3
  • C22H25N3O7S
  • C22H26ClN3O7S
  • pharmaceutical intermediates